Which Lab Tests Help Assess Longevity Risk?

TL;DR

Longevity testing is most useful when it assesses risks for atherosclerotic disease, cancer, and neurodegenerative disease rather than trying to predict an exact lifespan. Blood can reveal much about lipoproteins, inflammation, insulin, metabolism, and APOE status, but it provides limited insight into cancer, endothelial health, and toxin exposure, while imaging and specialized testing may become more useful with age.

Transcript

Welcome to The Qualies, a subscriber exclusive podcast. Qualies is just a shorthand slang for a qualification round, which is something you do prior to the race just a little bit quicker. Qualies podcast features episodes that are short, eh, we're hoping for less than 10 minutes each, which highlight the best questions, topics, tactics, et cetera, ... Read More

Key Insights

• Longevity blood testing is best organized around three major disease categories: atherosclerotic disease, cancer, and neurodegenerative disease. A standard blood panel cannot determine precisely how long someone will live, but selected measurements can help characterize risks associated with the conditions most relevant to lifespan.
• Cardiovascular disease risk is largely assessed through lipoproteins, inflammation, and endothelial dysfunction. Blood can provide substantial information about lipoproteins and inflammation, while endothelial health is harder to evaluate directly and may require indirect markers or additional testing beyond routine laboratory measurements.
• Lipoprotein assessment can include Lp, LDL particle number, small LDL particle number, and VLDL. The discussion emphasizes particle number rather than cholesterol alone, presenting these measurements as central components of estimating atherosclerotic risk from blood, particularly in younger people without an unusually extreme result.
• Inflammation can be evaluated with both nonspecific and specific blood markers. Fibrinogen and C-reactive protein are presented as nonspecific measures, while oxidized LDL, Lp-PLA2, and oxidized phospholipid measurements are described as more specific markers that may add useful cardiovascular-risk information.
• Blood results may explain roughly 80 to 85 percent of the needed cardiovascular-risk picture for an otherwise healthy 40-year-old without a dramatic abnormality. As patients age, CT angiograms may become more informative, while calcium scores have limitations because cardiovascular events can occur at non-calcified lesions.
• Cancer risk is the area where current blood testing provides the least insight. Most cancers result from somatic mutations rather than inherited germline mutations, so genotype testing is generally limited outside specific examples such as BRCA or Lynch, and fully functioning liquid biopsies are presented as a future need.
• APOE status can place a person into a broad low, medium, or high Alzheimer’s risk bucket. Additional assessment overlaps with cardiovascular and metabolic risk because Alzheimer’s disease has vascular and glucose-utilization components, while toxin-related risk remains especially difficult to measure using available tests.
• Fasting glucose is only a partial metabolic indicator because normal glucose does not directly establish normal insulin, especially after meals. Stress and cortisol can also influence morning glucose, while carbohydrate restriction can distort an oral glucose tolerance test unless carbohydrates are reintroduced before testing.

Questions & Answers

Q: What blood tests are most useful for assessing longevity risk?

The most useful blood tests are those that help characterize risks for atherosclerotic disease, cancer, and neurodegenerative disease. For cardiovascular risk, the discussion highlights Lp, LDL and small LDL particle numbers, VLDL, fibrinogen, C-reactive protein, oxidized LDL, Lp-PLA2, oxidized phospholipids, insulin, homocysteine, ADMA, and SDMA. APOE can also help classify Alzheimer’s risk.

Q: How can blood tests estimate cardiovascular disease risk?

Blood tests can examine three major contributors to cardiovascular disease: lipoproteins, inflammation, and endothelial dysfunction. Lipoprotein and inflammatory measurements provide considerable information, including particle numbers and both specific and nonspecific inflammatory markers. Endothelial health is harder to observe directly, although insulin, homocysteine, ADMA, and SDMA may provide indirect insight into processes affecting vascular function.

Q: Which lipoprotein and inflammation markers are discussed for longevity?

The lipoprotein measurements discussed include Lp, LDL particle number, small LDL particle number, and VLDL, with emphasis placed on particle number rather than cholesterol alone. Nonspecific inflammatory markers include fibrinogen and C-reactive protein. More specific markers mentioned include oxidized LDL, Lp-PLA2, and oxidized phospholipids, which can add information about inflammation related to cardiovascular risk.

Q: Why do cardiovascular assessments change as a person ages?

Blood may reveal much of the cardiovascular-risk picture in a younger person, with the discussion estimating roughly 80 to 85 percent for an otherwise healthy 40-year-old without a dramatic abnormality. As a patient becomes older, greater reliance may be placed on imaging such as CT angiograms. Calcium scores can help in younger patients but may miss non-calcified lesions.

Q: Why are blood tests limited for predicting cancer risk?

Blood currently provides relatively little direct insight into cancer risk because most cancers arise from somatic mutations rather than inherited germline mutations. Genotype information therefore has limited predictive value outside examples such as BRCA or Lynch. Until liquid biopsies based on RNA, DNA, or circulating proteins become fully functional, assessment mainly relies on inflammation and metabolic health.

Q: How does APOE testing relate to Alzheimer’s disease risk?

APOE status can place a patient into a broad low, medium, or high risk category for Alzheimer’s disease. That genetic information is only one part of assessment. The disease also has vascular and metabolic components, so cardiovascular risk factors and glucose-utilization concerns matter. Toxin-related factors are described as particularly difficult to measure with available testing.

Q: Can normal fasting glucose hide elevated insulin?

Normal fasting glucose does not directly prove that insulin is normal because glucose can be cleared while insulin is elevated, particularly after meals. A person with fasting glucose of 82 probably does not have very high fasting insulin, according to the discussion, but postprandial insulin can still be concerning. Measuring insulin provides more fine-tuned metabolic insight than fasting glucose alone.

Q: Why can a low-carbohydrate diet distort an oral glucose tolerance test?

A ketogenic or highly carbohydrate-restricted diet can produce very high glucose and insulin responses when a person suddenly receives an oral glucose challenge, despite low fasting glucose and insulin. The example describes repeating the test after eating 150 grams of carbohydrates from foods such as rice or potatoes for about three days, after which the result was normal.

Summary & Key Takeaways

• Blood testing for longevity should focus on the major disease risks that influence lifespan: atherosclerotic disease, cancer, and neurodegenerative disease. Cardiovascular risk is the area where blood provides the most information because lipoproteins, inflammatory markers, insulin, homocysteine, ADMA, and SDMA can reveal several important dimensions of vascular and metabolic health.

• Cancer risk is difficult to determine from routine blood work because most cancers arise from somatic rather than germline mutations. Genotype information therefore has limited value outside examples such as BRCA or Lynch. Until liquid biopsies become fully functional, inflammation, metabolic health, hyperinsulinemia, IGF, and IGFBP-3 offer only partial insight.

• APOE status can help place a person into a broad Alzheimer’s risk category, while cardiovascular and metabolic measurements provide additional context because the disease has vascular and glucose-utilization components. Fasting glucose alone can be misleading, so insulin patterns, dietary preparation, stress, cortisol, imaging, and sometimes specialized cognitive or cerebrospinal-fluid assessments require consideration.